XTX Topco Ltd Acquires Shares of 83,939 Omega Therapeutics, Inc. (NASDAQ:OMGA)

XTX Topco Ltd bought a new position in Omega Therapeutics, Inc. (NASDAQ:OMGA) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 83,939 shares of the company’s stock, valued at approximately $174,000. XTX Topco Ltd owned 0.15% of Omega Therapeutics as of its most recent filing with the SEC.

Separately, Ground Swell Capital LLC bought a new position in Omega Therapeutics during the second quarter valued at $40,000. Hedge funds and other institutional investors own 97.47% of the company’s stock.

Wall Street Analysts Forecast Growth

OMGA has been the subject of several analyst reports. Chardan Capital lowered their target price on shares of Omega Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Omega Therapeutics in a research report on Thursday, August 15th. Wedbush reiterated an “outperform” rating and issued a $12.00 price target on shares of Omega Therapeutics in a report on Wednesday, August 7th. Finally, Raymond James assumed coverage on Omega Therapeutics in a report on Tuesday, June 18th. They set an “outperform” rating and a $12.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Omega Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $10.20.

Omega Therapeutics Price Performance

OMGA opened at $1.22 on Tuesday. The company has a market capitalization of $67.29 million, a price-to-earnings ratio of -0.73 and a beta of 1.86. The company has a current ratio of 2.19, a quick ratio of 2.19 and a debt-to-equity ratio of 0.49. Omega Therapeutics, Inc. has a 12-month low of $1.19 and a 12-month high of $6.30. The business’s fifty day simple moving average is $1.50 and its 200-day simple moving average is $2.11.

Omega Therapeutics (NASDAQ:OMGA) last posted its earnings results on Tuesday, August 6th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. Omega Therapeutics had a negative net margin of 1,249.54% and a negative return on equity of 156.48%. The business had revenue of $2.13 million for the quarter, compared to the consensus estimate of $1.25 million. On average, equities research analysts anticipate that Omega Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Omega Therapeutics Company Profile

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.